Aderans Research Treats One-Hundredth Subject in Clinical Study
Aderans Research Institute Inc recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial’s 100th subject
Feb 2010
Aderans Research Institute Inc. (ARI) recently achieved a
significant milestone in its Phase 2 clinical study of cell-based
hair regeneration, treating the trial’s 100th subject. With clinical
sites expected to double in the coming months, the study will likely
add dozens of additional subjects to its enrollment.
“The breadth of this phase of our trial is tremendous,” said Kurt
Stenn, MD, Vice President and Chief Scientific Officer. “We have
significantly more participants than our Phase 1 study. The improved
quantity of our study group allows us to assess our cell-products
and accelerate our efforts to truly understand the impact of cell
regeneration on pattern hair loss.”
Phase 2 of the study has thus far been conducted in eight cities:
Atlanta, Boston, Chicago, New York, Paramus, Raleigh, Houston, and
Washington DC. The study will ultimately comprise at least 16 U.S.
metropolitan areas, with numerous new cities expected to be added in
the coming months.
The second phase of the trial is testing a variety of treatment
regimens designed to realize a unique autologous cell engineering
solution to hair regeneration. During the treatment, a small section
of hair-bearing tissue is removed, cells are extracted and
cultivated in a controlled laboratory setting, and then reintroduced
to the scalp, where they are expected to elicit new hair growth.
“This is leading edge research in our industry,” said Vern Liebmann,
Vice President, Operations. “We’ve been able to conduct this study
largely due to the generous financial backing of Aderans Co. LTD of
Japan, and we’re collectively very excited to see the results
beginning later this year.”
Phase 1 of the clinical study was conducted exclusively in the UK.
More than 30% of participants showed a viable response to ARI’s
cellular regeneration techniques.
About Aderans Research
Aderans Research is a pioneer in the research and development of
safe, effective cell engineered products for hair regeneration. With
offices in Atlanta and Philadelphia, Aderans Research Institute is a
subsidiary of Aderans Company, Ltd, the world’s largest wig
manufacturer, and an affiliate of Bosley, a global leader in medical
hair restoration.
More information on ARI’s study outcomes will be released as studies
unfold.
To see ARI’s latest clinical updates, please visit
http://aderansresearch.com/ari_clinicalupdates.html
Additional information on ARI can be found at
www.aderansresearch.com.
Related Links
.gif)
